Novel Therapeutic Options in CML
Tyrosine kinase inhibitors (TKIs) have turned chronic myeloid leukemia (CML) from a life-threatening malignancy worth the risk of an allogeneic stem cell transplant into a chronic condition. For most patients with chronic phase CML (CP-CML) life expectancy is now dictated by co-morbidities. As a result treatment paradigms for CML are changing, with more emphasis on quality of life, avoidance of long-term TKI toxicities and treatment free remission (TFR) as the key therapy objective rather than overall survival (OS).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Michael Deininger Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Toxicology | Transplants